drugset
drugset / Trial / NCT04933591

Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood

NCT04933591 ↗

Completed 30 enrolled Pirogov Russian National Research Medical University
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study is designed to find if the venoactive drug contained diosmin and hesperidin is able to work against chronic vein-specific inflammation by changing the level of Monocyte Chemoattractant Protein 1. This chemokine is involved in the vein wall remodeling in patients with lower limb varicose veins.

Timeline

Start
2020-09-01
Primary completion
2021-08-28
Completion
2021-09-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diosmin Small molecule 900 mg —
Comparator Hesperidin Small molecule 100 mg —

Indications

varicose disease